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Background: The aim of this study is to evaluate the associations between vascular endothelial growth factor
(VEGF) Single-nucleotide polymorphisms (SNPs) and clinical outcome in advanced gastric cancer patients treated
with oxaliplatin, 5-fluorouracil, and leucovorin (FOLFOX).
Methods: Genomic DNA was isolated from whole blood, and six VEGF (−2578C/A, -2489C/T, -1498 T/C, -634 G/C,
+936C/T, and +1612 G/A) gene polymorphisms were analyzed by PCR. Levels of serum VEGF were measured using
enzyme-linked immunoassays.
Results: Patients with G/G genotype for VEGF -634 G/C gene polymorphism showed a lower response rate (22.2%)
than those with G/C or C/C genotype (32.3%, 51.1%; P = 0.034). Patients with the VEGF -634 G/C polymorphism
G/C + C/C genotype had a longer progression free survival (PFS) of 4.9 months, compared with the PFS of
3.5 months for those with the G/G (P = 0.043, log-rank test). By multivariate analysis, this G/G genotype of VEGF
-634 G/C polymorphism was identified as an independent prognostic factor (Hazard ratio 1.497, P = 0.017).
Conclusion: Our data suggest that G/G genotype of VEGF -634 G/C polymorphism is related to the higher serum
levels of VEGF, and poor clinical outcome in advanced gastric cancer patients.
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Gastric cancer remains a significant health problem despite
of declining incidence in the West. It is the 4th most com-
mon cancer worldwide, accounting for 8.6% of all new
cancer diagnoses in 2002 [1]. Although the incidence of
stomach cancer among Korean has decreased over the past
two decades, gastric cancer is the most common carcin-
oma in men, and the third most common type of cancer in
women as a leading cause of cancer death in Korea [2].
In case of the patients who were most newly diagnosed
with gastric cancer or gastric cancer with distant metasta-
sis, the mean 5-year survival rate is recognized to be poor* Correspondence: yslee2@ncc.re.kr
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reproduction in any medium, provided the orat less than 10% [3]. Up to date, no randomized study on
combination chemotherapy has reported a median sur-
vival time exceeding 12 months [4]. 5-fluorouracil (5-FU)
has been used as a main chemotherapeutic agent for the
treatment of gastric cancer, and combination chemother-
apy with 5-FU has shown improved clinical outcomes.
Even though 5-FU with cisplatin is an effective agent, it
has been considered to have a high level of toxicity [4].
Oxaliplatin, another platinum based agent, has a more
favorable tolerability profile than cisplatin. The Folinic
acid/5-FU/Oxaliplatin combination (FOLFOX) has proven
to be an effective first- or second-line treatment agent for
advanced gastric cancer [5,6]. However, some patients are
predisposed to refractory diseases while others develop
resistance after the initial response. Patients may also
have a different severity of drug-related adverse events.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Patients’ characteristics
Variable Subgroup No. of patients %
Sex Male 125 65.8
Female 65 34.2
Age Median 55 years
Range (24–79 years)
ECOG performance status 0,1 186 97.9
2 4 2.1








Operation + 127 66.8
- 63 33.2
Adjuvant therapy + 79 41.6
- 111 58.4
No. of metastasis 1 106 55.8
2 54 28.4
> 3 30 15.8
CEA < 5 ng/ml 119 62.6
≥ 5 ng/ml 54 28.4
Unchecked 17 8.9
ECOG: eastern cooperative oncology group, CEA: carcinoembryonic antigen.
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diction of treatment response and survival may facilitate
customized chemotherapy and risk-related therapy, result-
ing in significantly enhanced survival rates.
Vascular endothelial growth factor (VEGF) is a well
known pro-angiogenic growth factor, and its stimulation
under hypoxic conditions plays a critical role in promot-
ing the survival of malignant cells in local tumor growth
and invasion, and in the development of metastases [7].
Several important roles of VEGF in the progression of
human gastric cancer have been reported. The expres-
sion of VEGF-A is correlated with tumor vascularity [8],
and the frequency of hepatic metastases increased sig-
nificantly among patients with VEGF positive tumors
[9]. The expression of VEGF-A is also correlated with a
poor outcome, and is an independent prognostic factor
in gastric cancer patients [8,9].
The VEGF gene is located on chromosome 6p21.3, and
contains eight exons being separated by seven introns.
Several single nucleotide polymorphisms (SNPs) have been
described in the VEGF gene some of which have been shown
to affect the expression of the gene [10]. Among these SNPs
there are five SNPs (−2578 C/A, -1154 G/A, -460 T/C in the
VEGF promoter region, +405 G/C in the 50-untranslated
region and +936C/T in the 30-untranslated region) that
are common and are related to VEGF protein synthesis
[11]. Very limited amount of published data on VEGF
polymorphisms in association with gastric cancer progno-
sis is available, and the results are diverging [12,13]. These
studies show an increased level of association of gastric
cancer and/or poor clinical outcomes in the subgroup
with genotypes, which would predict a higher level of
VEGF expression.
VEGF not only promotes neovascularization and mi-
gration but also increases vascular permeability and leak-
age [14]. This results in an elevated interstitial fluid
pressure that prevents effective transport of therapeutic
drugs into tumors and thereby, reduces the efficacy of
anti-cancer treatment. SNPs in VEGF may alter VEGF
protein concentrations, and may relate to inter-individual
variation in the risk and progression of selected tumors,
and their resistance to treatments. There were few reports
that showed the predictive value of VEGF polymorphism
to FOLFOX or capecitabine and oxalipatin (XELOX)
chemotherapy in colorectal cancer [15,16]. However, no
study that has investigated the SNPs of the VEGF gene,
and their relationship to the clinical outcomes of gastric
cancer patients treated with FOLFOX has yet been
published.
The purpose of the present study is to investigate
whether VEGF SNPs are associated with clinical out-
comes of patients with advanced gastric cancer trea-
ted with first-line FOLFOX palliative chemotherapy
or not.Methods
Study population
All patients in this study had histologically confirmed
adenocarcinoma of the stomach. These patients were
treated by FOLFOX chemotherapy. All patients who
were in their ages of 18 through 79 had a performance
status with a score less than or equal to two according
to the Eastern Cooperative Oncology Group scale, and
adequate bone marrow as well as renal function Previous
adjuvant chemotherapy must be completed at least
6 months before inclusion. Exclusion criteria included
the presence of central nervous system metastases, ser-
ious or uncontrolled concurrent medical illness, and a
history of other malignancies. Written informed consent
was obtained from each patient before study entry. The
use of all patient materials was approved by the institu-
tional review board of Dong-A University Hospital.
Patient characteristics
From March 2007 to August 2010, a total of 190
patients enrolled into this study. Demographic details on
the patients included in the study are shown in Table 1.
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their median age was 55 (ranging 24–79). Ninty-seven
patients underwent curative operation (stage I, 8; stage II,
28; stage III, 41; stage IV(M0), 20), and a palliative re-
section was done in 30-stage IV patients. Seventy-nine
patients (41.6%) received 5-FU-based adjuvant chemo-
therapy. Almost all patients had a good performance
status. No significant association was detected between
the genotypes of the SNPs and patient characteristics
(data not shown). Genotyping for the six VEGF po-
lymorphisms were obtained from all 143 patients. The
frequencies of each genotype are shown in Table 2.
Treatment protocols and dose modification
On day 1, oxaliplatin (85 mg/m2) was administered by
intravenous (i.v.) infusion in 500 ml of normal saline or
dextrose over 2 h. On day 1 and 2, leucovorin (20 mg/m2)
was administered as an i.v. bolus, immediately followed by
5-FU (400 mg/m2) given as a 10-min i.v. bolus, followed
by 5-FU (600 mg/m2) as a continuous 22-h infusion with
a light shield. Dose modifications of oxaliplatin or 5-FU
were made for hematologic, gastrointestinal, or neurologic
toxic effects on the basis of the most severe grade of tox-
icity that had occurred during the previous cycle. Treat-
ment could be delayed for up to 2 weeks if symptomatic
toxicity persisted, or if the absolute number of neutrophilsTable 2 Distribution of genotypes and serum levels of
vascular endothelial growth factor
Genotype Polymorphism No. of
patients
% Mean ± SD
(pg/ml)
P*
−2578C/A CC 116 61.1 453.2 ± 278.8 0.606
CA 63 33.2 520.0 ± 392.3
AA 11 5.8 523.9 ± 391.7
−2489C/T CC 116 61.1 453.2 ± 278.8 0.117
CT 60 31.6 478.4 ± 350.0
TT 14 7.4 724.0 ± 517.7
−1498 T/C TT 116 61.1 453.2 ± 278.8 0.563
TC 61 32.1 512.2 ± 400.7
CC 13 6.8 568.2 ± 324.9
−634 G/C GG 54 28.4 889.7 ± 453.7 0.004
GC 93 48.9 471.4 ± 222.6
CC 43 22.6 410.7 ± 222.6
+936C/T CC 135 71.1 440.0 ± 292.0 0.722
CT 45 23.7 495.5 ± 329.3
TT 10 5.3 502.6 ± 371.1
+1612 G/A GG 139 73.2 472.4 ± 339.2 0.371
GA 47 24.7 538.3 ± 295.9
AA 4 2.1 267.0 ± 159.3
*by Mann–Whitney.
SD: standard deviation.was < 1,500/μl or platelets count was < 100,000/μl. The
5-FU dose was reduced by 25% for subsequent courses
after National Cancer Institute Common Toxicity Criteria
(NCI-CTC) grade 3 diarrhea, stomatitis, or dermatitis had
occurred. The dose of oxaliplatin was reduced by 25% in
subsequent cycles if there were persistent paresthesias be-
tween cycles or paresthesias with functional impairment
lasting > 7 days. Treatment was continued until there
were signs of disease progression, unacceptable toxic
effects developed, or the patient refused further treatment.
Follow-up evaluation and assessment of response
Before each treatment course, a physical examination,
routine hematology, biochemistry, and chest X-ray were
carried out. Computed tomography scans to define the
extent of the disease, and the responses were carried out
after four cycles of chemotherapy, or sooner if there was
evidence of any clinical deterioration. Patients were
assessed before starting each 2-week cycle using the
NCI-CTC, except in the case of neurotoxicity. For the
neurotoxicity, an oxaliplatin-specific scale was used:
grade 1, paresthesias or dysesthesias of short duration,
but resolving before the next dosing; grade 2, paresthe-
sias persisting between doses (2 weeks); and grade 3,
paresthesias interfering with function.
Responses were evaluated using RECIST criteria.
Complete response (CR) was defined as the disappear-
ance of all evidences of disease and the normalization of
tumor markers for at least 2 weeks. Partial response
(PR) was defined as ≥ 30% reduction in uni-dimensional
tumor measurements, without the appearance of any
new lesions or the progression of any existing lesion.
Progressive disease (PD) was defined as any of the fol-
lowing: 20% increase in the sum of the products of all
measurable lesions, appearance of any new lesion, or
reappearance of any lesion that had previously disap-
peared. Stable disease (SD) was defined as a tumor
response not fulfilling the criteria for CR, PR, or PD.
Measurements of serum levels of VEGF
Blood sample was drawn from each participant through
venipuncture before chemotherapy and after three cycles
of treatment. The blood samples were centrifuged for
10 min at 3,000 r/min at −4°C. The serum was subse-
quently removed and stored at −80°C until biochemical
analysis. Serum VEGF enzyme-linked immunosorbent
assay (ELISA) was completed as per manufacturer proto-
cols (R&D Systems, Minneapolis MN). Briefly, serum
samples were thawed on wet ice three hours prior to
assay. Serum samples were pre-treated with an acidic so-
lution to promote dissociation of VEGF from abundant
VEGF binding proteins and stabilized in buffer and pre-
servatives. Samples were plated in 96 well format in du-
plicate after each of conjugated VEGF-1/HRP polyclonal
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tetramethylbenzidine) was then administered for thirty
minutes after the reaction was quenched with sulfuric
acid. Plates were read at an absorbance of 450 nm on a
Victor 3 plate reader (Perkin Elmer, Boston MA). Extra-
polated absorbance was analyzed using Masterplex
Readerfit ELISA software (Hitachi, Waltham MA) and
concentration was determined following a 4 Parameter
Logistic curve fit as per manufacturer’s recommenda-
tion. Measurements were made by the single investigator
blinded to the patients’ clinicopathological data.
DNA extraction and sample preparation
DNA was extracted from the 75 ul buffy coat using the
MagAttract DNA Blood Midi M48 Kit (Qiagen, Inc),
using a Qiagen BioRobot M48 workstation, according to
the manufacturer’s protocols automatically. The purity
and concentration of isolated DNA were determined
by NanodropW ND-1000 spectrophotometer (Nanodrop
technologies, DE, USA). Since we needed more detailed
quantity of each sample for genotyping reaction, we
measured the quantity of DNA using the Quant-iT™
PicoGreenW dsDNA Assay Kit (Molecular Probes, Inc.,
USA). We made dry plates for genotyping reaction with
10 ng in each well of 384 plates.
Candidate polymorphisms and primer design
SNPs were selected from the previous study (11). The
six SNPs analyzed were VEGF −2578 C/A SNP (rs699947),
VEGF −1498 C/A SNP (rs833061), VEGF −634 G/C
SNP (rs2010963), VEGF +936 C/T SNP (rs3025039), and
VEGF +1612 G/A SNP (rs10434). The multiplexed assay
group was designed to test up to 18 SNPs in the same
reaction group using MassARRAY Assay Designer v3.0
(Sequenom, CA).
Genotyping
Genotyping was carried out using the iPLEX Gold™
assay on the MassARRAYW Platform (Sequenom, CA).
PCR reactions were performed in a total volume of 5 ul
with 10 ng of genomic DNA, 1.625 mM MgCl2, 0.1 unit
of HotStarTaq polymerase (Qiagen, Valencia, CA),
0.5 mM dNTP (Invitrogen, Inc.), and 100 nM primers.
The PCR reactions started at 94°C for 15 min, followed
by 45 cycles at 94°C for 20 s, 50°C for 30 s, and 72°C for
1 min, with the final extension at 72°C for 3 min. Ampli-
fied PCR products were treated by SAP mixture in a
total 7ul with Shirimp Alkaline Phosphatase enzyme &
buffer. SAP reaction started at 37°C for 40 min and 85°C
for 5 min. The regions containing target SNP were amp-
lified by PCR and treated by SAP followed by single base
extension reaction, resulting in an allele-specific differ-
ence in mass between extension products. The extension
reactions were performed in a total volume of 9 ul with50 uM dNTP/dideoxynucleotide phosphate (ddNTP)
each, 0.063 unit/ul Thermo Sequenase (both from
SEQUENOM, Inc.), and 625 nM to 1.25uM extension
primers. Under the cycling conditions, two cycling loops,
one of five cycles that sits inside a loop of 40 cycles were
used. The sample was denatured at 94°C. Strands are
annealed at 52°C for 5 s and extended at 80°C for 5 s.
The annealing and extension cycle was repeated four
more times for a total of five cycles and then, looped
back to the 94°C denaturing step for 5 s. After then, the
5-cycle annealing and extension loop was conducted
again. The five annealing and extension steps with the
single denaturing step were repeated additional 39 times
for a total of 40. The 40 cycles of the 5-cycle annealing
and extension steps equate to a total of 200 cycles
(5 × 40). A final extension was done at 72°C for three
minutes and then, the sample wascooled down up to
4°C. After cleaning up the extension reaction products
with SpectroCLEAN, the products were transferred to
SpectroCHIP using SpectroPOINT and then, scanned
through SpectroREADER (MALDI-TOF). Resulting geno-
type data were collected by Typer v4.0 (Sequenom, CA).
Statistical analysis
Serum levels of VEGF were expressed as the means ±
standard deviation. Associations between VEGF SNPs
and levels of serum VEGF were assessed by Mann–
Whitney test. The association between VEGF SNPs and
response to chemotherapy was assessed by χ2 statistics.
The primary end point of the study was to investigate
the association between genotypes and progression-free
survival (PFS). The PFS and overall survival (OS) were
calculated from the date therapy started from the date of
disease progression and death, respectively. Patients who
were alive at the last follow-up were screened at that
time. Patients who were excluded from this study or
who died before progression were screened at the time
that they were excluded from this study. The association
of each marker with survival was analyzed using
Kaplan–Meier plots, the log-rank test, and its associated
95% confidence interval (CI) was calculated. Hazard
ratios (HRs) for survival, together with their 95% CI,
were calculated using Cox proportional hazards regres-
sion for age, gender, histological subgroup, performance
status, disease stage, and polymorphism subtype.
All tests were two-sided, and P < 0.05 was considered
statistically significant. Analyses were done using SPSS
version 14.0 (SPSS Inc, Chicago, IL).
Results
VEGF genotype and chemotherapy response
We analyzed the association of pretreatment serum levels
of VEGF with VEGF SNPs. Distribution of VEGF geno-
types and its serum levels of VEGF are shown in Table 2.
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of the -634 G/G genotype compared to G/C or C/C
(889.7 ± 453.7 vs. 471.4 ± 328.1 vs. 410.7 ± 222.6 pg/ml,
respectively, P = 0.004). None of the other tested SNPs
was associated with serum VEGF level.
The overall chemotherapy response rate for treatment
was 34.2% (95% CI: 20.0-40.5%). Six patients achieved
complete responses (3.2%), 59 patients achieved partial
responses (34.2%), 76 patients showed a stable condition
(40.0%) and 49 showed a progressive status (25.8%).
Lauren’s classification (P = 0.029) and number of metas-
tasis were related to the response to chemotherapy
(P = 0.034). Other parameters such as gender, age, previ-
ous operation, initial stage, adjuvant chemotherapy, and
carcinoembryonic antigen (CEA) level were not signifi-
cantly correlated with the clinical response to FOLFOX
chemotherapy. VEGF SNPs and its association with res-
ponses are summarized in Table 3. The VEGF-A −634 G/G
genotypes were related to inferior response rates com-
pared with G/C or C/C genotypes (22.2%, 32.3%, 51.1%,
respectively, P = 0.034). None of the other analyzed SNPs
predicted a response rate.Association of VEGF genotype and survival
The median duration of follow-up was 14.6 months
(ranging 1.0–48.3 months). The PFS was 4.5 months (95%Table 3 Response according to genotyping of vascular
endothelial growth factor
Genotype Polymorphism ORR % P*
−2578C/A CC 41/116 35.3 0.798
CA 20/63 31.7
AA 3/11 27.3
−2489C/T CC 41/116 35.3 0.812
CT 19/160 31.7
TT 4/14 28.6
−1498 T/C TT 41/116 30.8 0.832
TC 19/61 31.1
CC 4/13 35.3
−634 G/C GG 12/54 22.2 0.034
GC 30/93 32.3
CC 22/43 51.1
+936C/T CC 46/135 34.1 0.852
CT 14/45 31.1
TT 4/10 40.0
+1612 G/A GG 50/139 36.0 0.333
GA 12/47 25.5
AA 2/4 50.0
*by Fisher’s exact and chi-square test.
ORR: overall response rate.CI 3.8-5.1 months), and the median OS was 12.9 months
(95% CI 10.6-15.2 months). Among clinical parameters
evaluated, gender, previous operation, Lauren’s classifica-
tion, adjuvant chemotherapy, CEA were not correlated
with either PFS or OS. Patient’s age was related to both PFS
(P = 0.035) and OS (P = 0.011). Younger patients (less than
60 years of age) had better clinical outcomes. Table 4 shows
the association of VEGF SNPs with PFS and OS in the 190
patients analyzed. Patients with the VEGF -634 G/C poly-
morphism G/C +C/C genotype had a longer PFS of
4.9 months, compared with the PFS of 3.5 months for those
with the G/G (P = 0.043, Figure 1). No significant influence
on OS was observed by the VEGF −634 G/C. However,
other VEGF SNPs were not related to PFS, or OS.
Factors that had statistical significance in the uni-
variate models were included in multivariate model.
In multivariate analysis, age (hazard ratio (HR): 1.521,
95% CI: 1.105-2.093, P = 0.010), and number of metas-
tasis (HR: 1.375, 95%CI: 1.129-1.674, P = 0.002) re-
mained as independent prognostic factors for PFS.
The G/G genotype of -634 G/C polymorphism was
also identified as an independent prognostic factor
for PFS (HR: 1.497, 95% CI: 1.074-2.088, P = 0.017)
(Table 5). No other VEGF SNPs were significant in-
dependent prognostic factors impacted on PFS.Table 4 Univariate analysis according to the genotyping
of vascular endothelial growth factor







−2578C/A CC 116 4.9 0.676 12.8 0.423
CA 63 3.9 14.4
AA 11 3.0 11.5
−2489C/T CC 116 4.9 0.249 12.8 0.462
CT 60 4.0 14.4
TT 14 2.9 11.5
−1498 T/C TT 116 4.9 0.647 12.8 0.440
TC 61 3.9 13.7
CC 13 3.0 11.8
−634 G/C GG 54 3.5 0.043 13.1 0.407
GC 93 4.8 14.4
CC 43 4.9 11.5
+936C/T CC 135 4.5 0.925 13.1 0.711
CT 45 4.7 11.9
TT 10 3.9 11.9
+1612 G/A GG 139 4.4 0.448 12.8 0.644
GA 47 5.0 14.4
AA 4 2.1 10.6
*by log-rank test.
PFS: progression free survival, Mo: months, OS: overall survival.
Figure 1 Kaplan-Meier progression-free survival curve according to vascular endothelial growth factor -634 G/C polymorphisms
(P = 0.043).
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Identification of patients with potentially poor prognosis
after FOLFOX chemotherapy would help us to optimize
another treatment protocol for patients with advanced
gastric cancer. We reported that immunohistochemical
staining for Excision Repair Complementation 1 (ERCC1)
may be useful in prediction of the clinical outcome in
advanced gastric cancer patients treated with modified
FOLFOX4 [17]. We have also shown that the Glutathione
S-transferase M1 (GSTM1) positive genotype evidenced aTable 5 Multivariate analysis
Time to progression
Variable HR 95% CI p value*
Age 1.521 1.105–2.093 0.010
Gender 1.313 0.939–1.837 0.111
Performance 2.079 0.743–5.816 0.163
Operation 1.143 0.763–1.713 0.516
Stage 0.941 0.763–1.161 0.571
Lauren type 1.035 0.857–1.250 0.720
Number of metastasis 1.375 1.129–1.674 0.002
−634 G/C polymorphism 1.497 1.074–2.088 0.017
*by cox regression test.
VEGF: vascular endothelial growth factor.significantly better time to progression in cases of ad-
vanced gastric cancer being treated with FOLFOX [18].
The association of VEGF gene polymorphisms with
the risk or prognosis of gastric cancer has already been
shown [12,13]. In a Greek study, 634C/C genotype was
significantly associated with increased risk of gastric can-
cer development, and carrying the -634C/C genotype
was associated with decreased overall survival [12]. In a
Korean study, +936 T/T genotype had a worse overall
survival compared to C/C genotype, and the −460 T/C
or C/C genotype was a poor prognostic factor in patients
with stage 0 or I gastric cancer [13].
Previous studies have shown that VEGF expression is
related to the extent of tumor vascularization and prog-
nosis in solid tumors, and is predictive of resistance to
chemotherapy [19]. SNPs in the VEGF gene might influ-
ence the delivery of chemotherapy to the cancer cells
and may consequently hold predictive information in
relation to response [7]. There were several reports of
predictive value of VEGF SNPs for bevacizumab treated
patients [20-22]. Schultheis et al. [20] reported that
recurrent ovarian cancer patients with VEGF +937 T poly-
morphism C/T genotype had a longer PFS when treated
with cyclophosphamide and bevacizumab. Schneider et al.
[21] showed that VEGF -2578AA genotype was associated
with a superior median OS, and VEGF -1154A allele also
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vanced breast cancer with paclitaxel plus bevacizumab
treatment. Formica et al. [22] reported that VEGF -1154
G/A was an independent prognostic factor for PFS, and
VEGF −634 G/C was significantly associated with the
response rate in patients with metastatic colorectal cancer
patients receiving first-line treatment including fluoroura-
cil, irinotecan, and bevacizumab.
In this study, we assessed six common polymorphisms
of the VEGF genes and their association with response
and survival in metastatic gastric cancer patients treated
with FOLFOX. To our knowledge, this is the first study
to demonstrate a relationship between SNPs in the
VEGF gene and response to chemotherapy in patients
with metastatic gastric cancer. The genotype frequencies
of −634 G/C, -2578C/A, or +936C/T in the present
study corresponded to those reported in the literature
on Korean colorectal cancer patients [23-25], whereas
the frequency of the −1498 C/T genotype was similar to
that of the Japanese prostate cancer patients [26]. Any
minor variation could be explained by sample sizes.
There were two reports that showed the predictive
value of VEGF SNPs to FOLFOX or XELOX chemother-
apy in colorectal cancer [15,16]. The inferior response
rates and shorter PFS were shown in the patients with
VEGF −2578 C/A and 405 G/C genotype who were
treated with XELOX [15]. Other study showed that
VEGF −460 T/C or C/C genotypes were associated with
lower response rate to FOLFOX-4 and shorter survival
[16]. According to our study, only VEGF -634 G/G
genotype showed a significant association with lower
response rate and it was translated to short PFS. Shorter
overall survival was also shown in Korean colorectal
cancer patients with VEGF −634 G/G phenotype [27].
The VEGF −634 G/C likely affects expression at the
post-transcriptional level by altering the activity of the
internal ribosomal entry site B, thereby enhancing initi-
ation of translation at the AUG start codon and regula-
ting production of the large VEGF isoform, which is
translated at an alternative CUG codon [28]. Such
changes could be a possible explanation to the low re-
sponse rates, but several other mechanisms may also be
involved. However, we can not specify whether it was
the response to 5-FU, oxaliplatin or the combination of
both that seemed to be related to SNPs in the VEGF
gene or not in this study. None of the rest, of the exam-
ined SNPs conferred any clinical significance.
A few studies have reported that VEGF-634 G/C gene
polymorphisms are associated with VEGF production.
Nonetheless, the results are inconsistent. Awata et al.
[29] reported that individuals with the −634 C/C geno-
type had a higher fasting serum VEGF level than those
with other genotypes, and that they carried an increased
risk of diabetic retinopathy. Meanwhile, Watson et al.[10] showed that the −634 G allele is associated with
higher VEGF production than the +405C allele. In this
study, patients with -634 G/G genotypes were associated
with higher circulating VEGF levels.
Kim et al. showed that the e VEGF 936 T-allele were
associated with inferior survival rates, compared with
their corresponding genotypes. However, the VEGF +936
C/T genotype showed no relationship with response to
chemotherapy or survival in this study. Difference in
disease stages, and sample sizes could probably explain
some of these discrepancies.
Conclusion
To the best of our knowledge, this is the first prospect-
ive study that has explored the association between
VEGF SNPs and clinical outcomes of metastatic gastric
cancer patients treated with FOLFOX chemotherapy.
The results demonstrated obvious relationships between
genetic variations in the VEGF gene and response to
FOLFOX chemotherapy, which translated to a signifi-
cant difference in PFS.
Irinotecan and taxane-based regimens have been used
in the treatment of advanced gastric cancer patients,
with a similar survival to those attained with FOLFOX
[30,31]. Irinotecan or taxane-based regimens could be
the better alternative for patients with VEGF -634 G/G
genotype. These findings deserve confirmation in add-
itional prospective studies.
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